Key Developments For Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. (PGNX.O) (Consolidated Issue listed on NASDAQ Global Market)
Progenics Pharmaceuticals, Inc. Regains Worldwide Rights To RELISTOR Franchise From Wyeth's Wyeth Pharmaceuticals
Progenics Pharmaceuticals, Inc. announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth. Under which Progenics is regaining all worldwide rights to the RELISTOR franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals. Progenics will assume full control of future development and commercialization of subcutaneous RELISTOR after a one year transition, and will immediately take over ongoing development of the oral form of the drug. Under the terms of the transition agreement, Wyeth has agreed to: - Pay Progenics a total of $10 million in six quarterly installments to cover certain costs associated with the transition. - Exclusively license to Progenics, on a royalty-free basis, its rights to RELISTOR intellectual property that arose under the companies' 2005 License and Co-Development Agreement - Return to Progenics rights previously granted to it under the companies' 2005 Agreement. - Provide support by continuing manufacturing, marketing, sales, distribution, currently ongoing clinical studies and regulatory activities for subcutaneous RELISTOR.
Progenics Pharmaceuticals, Inc. Announces Promotion Of Mark R. Baker To President
Progenics Pharmaceuticals, Inc. announced the promotion of Mark R. Baker to the newly created position of President. Mr. Baker was also appointed to the Board of Directors.
Progenics Pharmaceuticals, Inc. and Wyeth's Wyeth Pharmaceuticals Announce Submission Of Supplemental New Drug Application
Progenics Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) and an extension application to the European Union (E.U.) European Medicines Agency (EMEA) for RELISTOR (methylnaltrexone bromide) subcutaneous injection for a new delivery system, pre-filled syringes.
Progenics Pharmaceuticals, Inc. Announces Workforce Reduction
Progenics Pharmaceuticals, Inc. announced that it has acheived a planned 10% staffing reduction, which brings headcount to 224.
Progenics Pharmaceuticals, Inc. Selects Subcutaneous Form of PRO 140 for Further Development
Progenics Pharmaceuticals, Inc. announced that it has selected for further development the subcutaneous form of PRO 140 for the treatment of HIV infection. The decision follows positive results from a recently completed phase 2 clinical trial as well as feedback from key opinion leaders, treatment advocates and people living with HIV. Results from the phase 2 study were presented late yesterday at the 16thConference on Retroviruses and Opportunistic Infections (CROI) in Montreal. In this clinical trial, the subcutaneous dosage form of PRO 140 demonstrated potent and highly significant antiviral effects compared to placebo at all doses of active drug examined and was generally well tolerated.
